Karuna

Karuna’s schizophrenia drug succeeds in a second late-stage trial
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Karuna
clinical trials
schizophrenia
KarXT
Flag link:
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Biopharma Dive
Karuna
schizophrenia
KarXT
Flag link:
Back to business for biotech flotations
Back to business for biotech flotations
EP Vantage
IPOs
BridgeBio
Turning Point Therapeutics
Stoke Therapeutics
Prevail Therapeutics
Atreca
NGM Biopharmaceuticals
Akero Therapeutics
Milestone Pharmaceuticals
Morphic Therapeutics
Karuna
Flag link:
Puretech-backed Karuna makes Nasdaq debut with $89M IPO
Puretech-backed Karuna makes Nasdaq debut with $89M IPO
Endpoints
Karuna
IPOs
NASDAQ
PureTech
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link:
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Karuna
schizophrenia
Alzheimer's disease
Flag link:
Schizophrenia therapy developer Karuna seeking IPO
Schizophrenia therapy developer Karuna seeking IPO
BioCentury
IPOs
Karuna
antipsychotics
schizophrenia
Flag link:
Karuna looks past schizophrenia with $68M series B
Karuna looks past schizophrenia with $68M series B
BioCentury
Karuna
KarXT
schizophrenia
geriatric psychosis
pain
Flag link: